WeVote
Log In

Bill

RB

Bill

S 2283

"Psilocybin Behavioral Health Access and Services Act"; authorizes production and use of psilocybin to promote health and wellness.*

2024-2025 Regular Session Introduced by Renee Burgess and 8 co-sponsors

New Jersey bill authorizes regulated psilocybin production and clinical administration by licensed providers for treating mental health conditions despite federal prohibition.

Reported out of Senate Committee with Amendments, 2nd Reading
#health
0
WeVote Research Nonpartisan
Bill Summary · S 2283

Legislative bill overview

S 2283 establishes a regulated framework in New Jersey allowing licensed healthcare providers to produce and administer psilocybin (a controlled psychedelic compound) under clinical supervision for treating behavioral and mental health conditions. The bill creates a licensing system, sets safety protocols, and defines eligible medical conditions for psilocybin-assisted therapy.

Why is this important

This represents a significant shift in drug policy at the state level, potentially making New Jersey an early adopter of psychedelic-assisted medicine. The bill could provide treatment options for patients with conditions like treatment-resistant depression, PTSD, and end-of-life anxiety where traditional therapies have limited effectiveness, while also generating tax revenue and creating regulated medical oversight rather than black-market access.

Potential points of contention

  • Federal-state legal conflict: Psilocybin remains a Schedule I controlled substance under federal law, creating legal ambiguity and potential enforcement complications for state-licensed providers and patients
  • Safety and standardization concerns: Questions remain about optimal dosing protocols, long-term effects, patient screening criteria, and liability protections if adverse outcomes occur during clinical use
  • Access and equity: Concerns about whether psilocybin-assisted therapy would be covered by insurance, creating barriers for lower-income patients, and whether licensing requirements would concentrate services among wealthy areas
  • Regulatory oversight gaps: The bill's specifics on provider training requirements, facility standards, and ongoing monitoring mechanisms may be insufficient given the novel nature of legal psychedelic medicine

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.